Director at CRISPR Therapeutics (CRSP) receives 13,000 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
CRISPR Therapeutics AG reported that director Harold Edward Fleming received a grant of stock options covering 13,000 common shares. The options have an exercise price of 51.84 per share and expire on June 5, 2036. Subject to continued service, they vest in 12 equal monthly installments, beginning with the first installment on June 30, 2026 and the last on the earlier of the one-year anniversary of the grant date or the 2027 annual meeting.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Fleming Harold Edward
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 13,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 13,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 13,000 options
Exercise price: 51.84 per share
Expiration date: June 5, 2036
+3 more
6 metrics
Option grant size
13,000 options
Stock Option (Right to Buy) granted to director
Exercise price
51.84 per share
Exercise price for underlying common shares
Expiration date
June 5, 2036
Options expire on this date
Underlying shares
13,000 common shares
Shares underlying the stock options
Post-transaction derivative holdings
13,000 options
Total options held following the reported transaction
Vesting schedule
12 monthly installments
First on June 30, 2026; last by 2027 annual meeting
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, vesting
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 51.8400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-05T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"the options will vest and become exercisable in 12 equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did CRISPR Therapeutics (CRSP) disclose in this Form 4 for Harold Edward Fleming?
CRISPR Therapeutics reported that director Harold Edward Fleming received a grant of stock options for 13,000 common shares. These options were awarded as compensation and are not an open-market purchase of existing shares.
What is the exercise price and expiration date of Harold Edward Fleming’s CRSP stock options?
The options granted to Harold Edward Fleming have an exercise price of 51.84 per share and expire on June 5, 2036. He can only benefit if CRISPR Therapeutics’ share price exceeds this level before expiration.
How do Harold Edward Fleming’s CRISPR Therapeutics options vest over time?
The options vest in 12 equal monthly installments, subject to continued service. The first installment vests on June 30, 2026, and the last vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 annual meeting.